Overview

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

Status:
Recruiting
Trial end date:
2021-03-15
Target enrollment:
Participant gender:
Summary
Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
Phase:
Phase 4
Details
Lead Sponsor:
David Garcia Cinca
Collaborator:
Dr. Josep Mallolas
Treatments:
Lamivudine
Tenofovir